Compare TG Therapeutics Inc (TGTX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Xpeng Inc - ADR — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Xpeng Inc - ADR trades at $13.38 (market cap $12.96B). The key difference: Xpeng Inc - ADR is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| TGTX | XPEV | |
|---|---|---|
Market Cap | $8.26B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $28.07 |
52-Week Low | $26.39 | $12.09 |
Enterprise Value | $8.50B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPeng (XPEV) trades at $13.33, down 1.52% today, with a bearish technical signal and neutral oscillators. Revenue grew to $76.72B in 2025, but net income remained negative at -$1.14B, with improving margins. Recent news highlights global expansion, including the L03 SUV launch in Munich and Robotaxi testing, while Q2 2026 deliveries of 103,295 vehicles beat expectations, signaling demand recovery.
The stock offers upside to the $17.00 analyst target but faces risks from intense EV competition and persistent losses. Investor sentiment is mixed, with 64.7% of analysts rating it Buy, yet technical trends and cash flow volatility warrant caution. Key catalysts include new model launches and international growth, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
